Next-Generation Sequencing (NGS) Test: Gene Panels, Variants, and Results

Next-generation sequencing (NGS) is a laboratory method that reads millions of DNA or RNA fragments in parallel. In clinical care, it can examine many genes at once, search for a cause of an inherited condition, profile a tumor, identify an infectious organism, or help explain an unusual response to medication. The phrase “NGS test” does not describe one single assay. It can refer to a focused gene panel, an exome test, a genome test, an RNA-based fusion assay, or another test built on high-throughput sequencing.

The value of an NGS result depends on more than the sequencer. The chosen genes, sample quality, read depth, bioinformatics pipeline, variant-classification rules, and the patient’s clinical history all shape what the report can and cannot establish. A positive result may confirm a diagnosis or reveal a treatment target, while a negative result may still leave important possibilities open. Understanding the test’s scope and limitations is therefore essential before interpreting any finding.

• NGS can analyze dozens to thousands of genes in one test, but the exact genes and variant types differ by laboratory and panel.
• A pathogenic or likely pathogenic variant may support a diagnosis, although inheritance pattern, symptoms, and family history must still fit.
• A negative result does not rule out every genetic cause, especially variants outside the test’s target regions or below its detection limit.
• A variant of uncertain significance is not a confirmed diagnosis and usually should not be used alone for major medical decisions.
• Most blood or saliva tests need little preparation, while tumor testing depends heavily on tissue quality and the percentage of tumor cells.

Table of Contents

• What an NGS Test Measures
• Gene Panels, Exomes, and Genomes
• From Sample to Sequence Result
• Variants NGS Can and Cannot Detect
• How NGS Results Are Interpreted
• Accuracy, Limitations, and False Results
• Preparation, Cost, Timing, and Follow-Up

What an NGS Test Measures

An NGS test determines the order of nucleotide bases in selected pieces of DNA or RNA. DNA uses the bases A, C, G, and T; RNA uses U in place of T. A laboratory compares the generated sequence with a reference sequence and looks for differences called variants. The test may examine inherited DNA from blood or saliva, acquired changes in a tumor, microbial genetic material, or gene activity represented by RNA.

Unlike traditional sequencing methods that usually read one region at a time, NGS handles a very large number of fragments in the same run. Each fragment may be read repeatedly. Those overlapping reads allow software to reconstruct the sequence and estimate how confidently a difference is present.

Several quality terms appear on NGS reports:

• Read depth or coverage depth is the number of times a position was read. A depth of 100× means that roughly 100 sequence reads cover that position, although usable depth may be lower after quality filtering.
• Breadth of coverage is the percentage of the intended target that reached the laboratory’s minimum quality threshold.
• Variant allele fraction is the proportion of reads containing a variant. A heterozygous germline variant often appears near 50%, but biology and technical factors can shift that percentage. In tumors, the fraction may be much lower because the sample includes normal cells and different tumor-cell populations.
• Limit of detection is the lowest variant level the validated assay can identify reliably. It is assay-specific, not a universal property of NGS.

NGS is a platform rather than a diagnosis. The same sequencing chemistry may support a hereditary-cardiomyopathy panel, a solid-tumor panel, an epilepsy panel, or a broad genetic panel test. What changes is the target design, sample type, analysis pipeline, reporting policy, and clinical question.

A clinician may order NGS when many genes can cause similar symptoms, when several biomarkers need to be assessed from limited tissue, or when earlier testing did not find an answer. It may also be used after a diagnosis to guide medication selection, estimate prognosis, identify relatives who may benefit from testing, or determine eligibility for a clinical trial.

Gene Panels, Exomes, and Genomes

The most important choice is not simply whether to use NGS, but how much of the genome to examine and what the laboratory agrees to analyze.

Targeted gene panels

A targeted panel includes genes selected for a defined condition or clinical purpose. A hereditary breast and ovarian cancer panel may contain a few high-penetrance genes or dozens of genes with different levels of evidence. A cardiomyopathy panel, meanwhile, may include genes linked to overlapping heart-muscle disorders.

Panels often provide high read depth, relatively focused interpretation, lower cost, and a manageable number of incidental findings. They work well when the clinical picture points to a known group of genes. Their main weakness is that they cannot detect a disease-causing change in a gene that was not included or was not fully covered. Panel content also differs among laboratories, so two tests with similar names may not be equivalent.

Exome sequencing

The exome contains the protein-coding portions of genes and nearby splice regions. It represents only a small percentage of the genome but includes many known disease-causing variants. Whole-exome sequencing is often considered when symptoms are complex, several diagnostic categories overlap, or a focused panel has been unrevealing.

Exome analysis may be performed as a singleton test on one person or as a duo or trio that includes one or both biological parents. Trio testing can help determine whether a variant is inherited or new in the child, whether two variants lie on opposite gene copies, and whether a finding tracks with the expected inheritance pattern.

Genome sequencing

Genome sequencing examines coding and noncoding DNA more broadly. It may provide more even coverage than capture-based exome testing and can improve detection of some structural, intronic, mitochondrial, and copy-number changes. However, a genome test does not automatically interpret every base. Laboratories usually restrict analysis to regions and variant types that have validated clinical meaning.

A broader test produces more data but not always a clearer answer. The diagnostic yield depends on the person’s phenotype, family structure, prior testing, ancestry representation in reference databases, and the laboratory’s analytic capabilities. Broader testing can also create more uncertain or secondary findings. Consent discussions should explain whether the laboratory reports medically actionable findings unrelated to the original reason for testing.

DNA versus RNA sequencing

DNA sequencing identifies changes in the underlying genetic code. RNA sequencing can show whether a gene is expressed, whether exons are joined incorrectly, or whether two genes form a fusion transcript. RNA may clarify the effect of a suspected splice variant or detect a rearrangement that is difficult to characterize from DNA alone. The useful sample type matters: blood RNA may not express a gene that is active only in muscle, brain, or tumor tissue.

The best test is the narrowest assay that can answer the clinical question without missing likely causes. A focused panel may be ideal for a well-defined disorder, while exome, genome, or combined DNA/RNA testing may be more suitable for a genetically heterogeneous condition.

From Sample to Sequence Result

NGS involves several linked laboratory and computational stages. A weakness at any stage can affect the final report.

1. Sample collection and identity checks. Germline testing commonly uses blood, saliva, or a cheek swab. Tumor testing may use formalin-fixed tissue, fresh tissue, bone marrow, blood, or circulating cell-free DNA. The laboratory confirms labeling, sample volume, and acceptance criteria.
2. Nucleic-acid extraction. DNA or RNA is separated from cells and assessed for quantity, purity, and fragmentation. Old paraffin-embedded tumor tissue may contain damaged DNA, while saliva may contain bacterial DNA or yield less human DNA than expected.
3. Library preparation. The nucleic acid is fragmented when needed, and short adapter sequences are attached. Adapters allow fragments to bind to the sequencing system and may include molecular barcodes that help distinguish true low-level variants from technical errors.
4. Target selection. Amplicon-based methods use PCR to copy selected regions. Hybrid-capture methods use probes to pull down regions of interest. Genome sequencing usually avoids target capture, although the laboratory still defines which regions it will analyze and report.
5. Sequencing. The instrument reads bases from millions of library fragments. Different platforms use different chemistries, read lengths, and error profiles.
6. Bioinformatics. Software checks read quality, aligns reads to a reference genome, removes or accounts for duplicates, calls variants, annotates them, and applies filters. Specialized algorithms may evaluate copy number, structural changes, fusions, mosaic variants, or mitochondrial heteroplasmy.
7. Clinical interpretation. Laboratory scientists and medical professionals assess the evidence for each reportable variant, the associated disease, inheritance pattern, penetrance, and fit with the patient’s features.
8. Report generation and quality review. The report states findings, interpretation, methods, limitations, and recommendations. Some findings are confirmed with an independent method when validation data, sample quality, variant type, or laboratory policy makes confirmation appropriate.

Turnaround time commonly ranges from about one to eight weeks for hereditary testing, although rapid hospital-based sequencing may be completed in days and complex cases may take longer. Tumor panels often return in one to three weeks when adequate material is available. These ranges vary widely by laboratory, insurance authorization, sample transport, data review, and whether extra studies are needed.

The raw sequence data are not the same as the clinical result. A variant-call file may contain thousands of differences, most of which are common or harmless. The report is a medically curated subset shaped by the test indication and reporting policy.

Variants NGS Can and Cannot Detect

Most clinical short-read NGS assays are strongest at detecting single-nucleotide variants and small insertions or deletions within well-covered target regions. Some assays also identify larger deletions, duplications, copy-number changes, selected structural variants, mitochondrial variants, and low-level mosaic or tumor variants. The report should state which categories were validated.

Variant type	What it means	Typical performance or limitation
Single-nucleotide variant	One DNA base is replaced by another	Usually detected well in adequately covered regions
Small insertion or deletion	A short stretch of bases is added or removed	Often detected, but performance can drop in repetitive or complex sequence
Copy-number variant	One or more exons or genes are deleted or duplicated	Possible with validated depth-based analysis; sensitivity varies by size and assay
Structural variant	A large segment is inverted, moved, duplicated, or joined elsewhere	Some are found through discordant or split reads; balanced and repetitive events may be missed
Repeat expansion	A short sequence is repeated too many times	Often requires a dedicated assay; many short-read panels do not size large expansions reliably
Mosaic or low-level variant	The variant is present in only a fraction of cells or molecules	Detection depends on depth, error suppression, tissue tested, and validated allele-fraction threshold

Difficult regions include genes with highly similar pseudogenes, GC-rich segments, homopolymers, repetitive DNA, low-complexity sequence, and regions with poor probe capture or alignment. Some medically important loci require custom methods because short reads cannot be assigned confidently to the correct copy of the gene.

NGS may also miss epigenetic changes such as abnormal methylation, large repeat expansions, balanced chromosome rearrangements, low-level mosaicism, or variants deep within noncoding DNA if the test was not designed for them. A negative panel can therefore lead to another method, such as deletion/duplication analysis, a repeat expansion test, chromosomal microarray, methylation testing, RNA analysis, or long-read sequencing.

Sample choice creates another limitation. A germline blood test may not detect a variant confined to a tumor. Conversely, a tumor test can reveal a variant that may be inherited, but tumor-only testing usually cannot prove whether it is germline. Confirmatory testing on blood, saliva, cultured skin cells, or another non-tumor sample may be recommended.

How NGS Results Are Interpreted

A sequence difference becomes clinically meaningful only after evidence is evaluated. For inherited-disease testing, laboratories commonly use five categories: pathogenic, likely pathogenic, variant of uncertain significance, likely benign, and benign. Cancer laboratories may use a tiered system based on diagnostic, prognostic, and treatment relevance.

Positive or diagnostic result

A pathogenic or likely pathogenic variant can establish or support a diagnosis when the gene, inheritance pattern, and patient’s findings align. In an autosomal dominant disorder, one disease-causing variant may be sufficient. In an autosomal recessive disorder, two disease-causing variants usually must affect opposite gene copies. For an X-linked disorder, interpretation depends on the person’s chromosomes, sex-related biology, and the condition’s expression pattern.

A positive result may influence surveillance, treatment, reproductive planning, and testing of relatives. It does not always predict age of onset or severity. Reduced penetrance means some people with a disease-associated variant never develop the condition. Variable expression means affected relatives can have different symptoms.

Negative result

A negative result means the laboratory did not find a reportable variant within the tested scope. It may reduce the likelihood of certain diagnoses, particularly when the assay has high sensitivity for a well-defined familial variant. It does not prove that symptoms are non-genetic.

Reasons for a negative result include a gene not included in the panel, a variant type the method cannot detect, insufficient coverage, a condition not yet linked to a known gene, a multifactorial cause, or an incorrect initial diagnosis. Reanalysis may help as gene-disease knowledge and classification evidence change.

Variant of uncertain significance

A variant of uncertain significance, or VUS, has too little or conflicting evidence to be labeled harmful or harmless. It should not be treated as a positive diagnosis. Testing selected relatives, reviewing detailed clinical features, functional studies, or waiting for new population and case data may help resolve it.

The chance of receiving a VUS generally rises with larger panels and broader testing. It may also be higher in people whose ancestry is underrepresented in genomic databases. That disparity reflects data limitations, not greater biological uncertainty in the person.

Secondary, incidental, and unexpected findings

Exome and genome tests may identify medically important variants unrelated to the original indication. Consent policies differ on whether a patient can opt in or out of certain secondary findings. Tests can also uncover unexpected biological relationships, such as nonparentage or close parental relatedness, depending on the family samples and analysis.

The report should be read as a clinical document, not as a list of mutations. Important fields include the gene and transcript, standardized DNA and protein notation, zygosity or allele fraction, classification, associated condition, inheritance pattern, evidence summary, test limitations, and recommended follow-up.

Accuracy, Limitations, and False Results

Analytical accuracy describes whether the assay detects a variant that is truly present in the sample. Clinical validity describes how reliably the variant is associated with a condition or treatment response. Clinical utility asks whether using the result improves care. These are related but distinct questions.

A laboratory validates its assay using reference samples and measures sensitivity, specificity, precision, reproducibility, reportable range, and limit of detection. Performance is usually very high for common variant types in well-covered regions, but an overall percentage can hide weaker performance in difficult genes or variant classes. The most useful question is whether the assay is validated for the exact variant type and specimen involved.

False-negative results can occur when:

• the target region has inadequate coverage;
• the variant lies outside the analyzed region;
• the allele fraction is below the detection threshold;
• a large insertion, repeat, or rearrangement cannot be resolved by short reads;
• tumor content is too low or DNA is highly degraded;
• the wrong tissue was tested for mosaicism;
• alignment software assigns reads incorrectly in a duplicated region.

False-positive results are less common in validated clinical testing but may result from sequencing artifacts, DNA damage, contamination, sample mix-up, index misassignment, alignment errors, or overly permissive variant calling. Formalin fixation can produce characteristic DNA changes in tumor samples. Molecular barcodes, replicate evidence, manual review, and orthogonal confirmation can reduce these risks.

Interpretive error is separate from analytic error. A variant may be detected correctly yet classified incorrectly because evidence is incomplete, conflicting, or outdated. Laboratories may reach different classifications after weighing population frequency, functional data, segregation, computational predictions, and published cases. ClinVar and other shared databases improve transparency, but entries can conflict and must be assessed in context.

Quality indicators worth checking include the percentage of target bases meeting minimum depth, whether poorly covered regions were filled by another method, the assay’s ability to detect copy-number changes, and whether the report lists genes or exons with limited analysis. For tumor testing, the pathology review, estimated tumor percentage, and assay limit of detection are especially important.

A consumer raw-data file is not equivalent to a clinical NGS test. Consumer genotyping or sequencing may use different quality standards, target fewer medically relevant regions, and provide automated interpretations without full clinical context. A medically significant finding generally needs confirmation in an accredited clinical laboratory before care changes.

Preparation, Cost, Timing, and Follow-Up

Most germline NGS tests do not require fasting or medication changes. The practical preparation is informational: gather personal diagnoses, age at symptom onset, pathology reports, imaging, previous genetic results, and a three-generation family history when possible. Accurate clinical details help the laboratory choose genes and interpret variants.

For tumor testing, the oncology and pathology teams select the best specimen. A newer or more cellular tumor block may provide better DNA than a tiny, heavily treated, or necrotic sample. When tissue is limited, the team may prioritize tests or consider a liquid biopsy, recognizing that a negative blood result can reflect low tumor DNA shedding rather than absence of the variant.

Before testing, ask:

• Which genes and variant types are included?
• Does the test assess deletions, duplications, mitochondrial DNA, repeat expansions, or fusions?
• Will the laboratory report VUS findings?
• Are secondary findings offered, and can they be declined?
• What happens if a medically important region has low coverage?
• Is parental or family testing included when it helps interpretation?
• Who will explain the result and arrange follow-up?

Cost ranges from several hundred to several thousand U.S. dollars, depending on the assay, laboratory, insurance contract, and whether family samples or additional analyses are included. The billed amount may differ greatly from the negotiated or self-pay price. Prior authorization does not always guarantee full coverage, so a written estimate can prevent surprises.

Follow-up depends on the result. A pathogenic germline finding may lead to specialist care, screening changes, reproductive counseling, and targeted testing for relatives. A tumor finding may direct an approved therapy, support trial eligibility, or clarify prognosis. A VUS usually calls for clinical management based on symptoms and family history rather than the uncertain variant. A negative result may prompt another method, reanalysis, or a reassessment of the working diagnosis.

Results can change in meaning. Laboratories may reclassify a variant or offer periodic reanalysis, but notification practices vary. Keep a copy of the complete report, not only a patient-portal summary. Ask how updates are communicated and whether the ordering clinic should be contacted every one to three years when the diagnosis remains unresolved.

Genetic counseling is especially useful before broad testing, predictive testing in an unaffected person, testing involving children, or any result that may affect relatives. Counseling can clarify possible outcomes, privacy concerns, family communication, and the difference between finding a variant and predicting a person’s future health.

References

• NGS Approaches in Clinical Diagnostics: From Workflow to Disease-Specific Applications 2025 (Review)
• Quality assurance for next-generation sequencing diagnostics of rare neurological diseases in the European Reference Network 2024 (Review)
• Clinical Utility and Benefits of Comprehensive Genomic Profiling in Cancer 2024 (Review)
• Next-generation sequencing in pharmacogenomics – fit for clinical decision support? 2024 (Review)
• Next-generation sequencing for constitutional variants in the clinical laboratory, 2021 revision: a technical standard of the American College of Medical Genetics and Genomics (ACMG) 2021 (Technical Standard)
• Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology 2015 (Guideline)

Disclaimer

NGS results require interpretation by qualified laboratory and clinical professionals in the context of the person’s history, family history, specimen quality, and test limitations. Do not start, stop, or change treatment or medical surveillance based only on an online explanation or an unconfirmed result. A genetics professional or relevant specialist can explain what the report means for the tested person and relatives.